Abstract
Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.
Original language | English |
---|---|
Pages (from-to) | 1333-1338 |
Number of pages | 6 |
Journal | Clinical calcium |
Volume | 26 |
Issue number | 9 |
Publication status | Published - 01-09-2016 |
All Science Journal Classification (ASJC) codes
- General Medicine